Guangdong Hybribio Biotech Co Ltd (300639) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.018x

Based on the latest financial reports, Guangdong Hybribio Biotech Co Ltd (300639) has a cash flow conversion efficiency ratio of 0.018x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥66.39 Million ≈ $9.71 Million USD) by net assets (CN¥3.73 Billion ≈ $545.62 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of Guangdong Hybribio Biotech Co Ltd to measure how much of total assets are equity-financed.

Guangdong Hybribio Biotech Co Ltd - Cash Flow Conversion Efficiency Trend (2012–2025)

This chart illustrates how Guangdong Hybribio Biotech Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check how high is Guangdong Hybribio Biotech Co Ltd's earnings quality to evaluate the quality of earnings relative to operating cash generation.

Guangdong Hybribio Biotech Co Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Guangdong Hybribio Biotech Co Ltd ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
CoinShares International Ltd ST:CS	-0.162x
Chang Lan Electric Technology Co Ltd SHE:002879	0.062x
SandRidge Energy Inc NYSE:SD	0.038x
Pony Testing International Group Co SHE:300887	0.041x
Fujian Rongji Software Co Ltd SHE:002474	-0.005x
Semco Technologies Sas PA:ALSEM	N/A
Shengtak New Material Co Ltd SHE:300881	-0.093x
Lifecome Biochemistry Co Ltd SHE:002868	-1.583x

Annual Cash Flow Conversion Efficiency for Guangdong Hybribio Biotech Co Ltd (2012–2025)

The table below shows the annual cash flow conversion efficiency of Guangdong Hybribio Biotech Co Ltd from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Guangdong Hybribio Biotech Co Ltd.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	CN¥3.66 Billion ≈ $535.84 Million	CN¥341.61 Million ≈ $49.99 Million	0.093x	+379.19%
2024-12-31	CN¥4.05 Billion ≈ $592.14 Million	CN¥78.78 Million ≈ $11.53 Million	0.019x	-68.94%
2023-12-31	CN¥5.10 Billion ≈ $746.11 Million	CN¥319.60 Million ≈ $46.77 Million	0.063x	-74.98%
2022-12-31	CN¥5.23 Billion ≈ $764.86 Million	CN¥1.31 Billion ≈ $191.58 Million	0.250x	+37.87%
2021-12-31	CN¥3.48 Billion ≈ $508.50 Million	CN¥631.34 Million ≈ $92.39 Million	0.182x	+47.91%
2020-12-31	CN¥2.53 Billion ≈ $370.84 Million	CN¥311.30 Million ≈ $45.55 Million	0.123x	+28.97%
2019-12-31	CN¥1.18 Billion ≈ $173.35 Million	CN¥112.83 Million ≈ $16.51 Million	0.095x	+27.97%
2018-12-31	CN¥1.08 Billion ≈ $158.05 Million	CN¥80.39 Million ≈ $11.76 Million	0.074x	-8.72%
2017-12-31	CN¥970.90 Million ≈ $142.07 Million	CN¥79.17 Million ≈ $11.58 Million	0.082x	-35.72%
2016-12-31	CN¥501.67 Million ≈ $73.41 Million	CN¥63.63 Million ≈ $9.31 Million	0.127x	+8.26%
2015-12-31	CN¥413.71 Million ≈ $60.54 Million	CN¥48.47 Million ≈ $7.09 Million	0.117x	+16.51%
2014-12-31	CN¥344.60 Million ≈ $50.43 Million	CN¥34.65 Million ≈ $5.07 Million	0.101x	-15.93%
2013-12-31	CN¥191.38 Million ≈ $28.01 Million	CN¥22.89 Million ≈ $3.35 Million	0.120x	-3.12%
2012-12-31	CN¥130.29 Million ≈ $19.06 Million	CN¥16.08 Million ≈ $2.35 Million	0.123x	--

About Guangdong Hybribio Biotech Co Ltd

SHE:300639 China Diagnostics & Research

Market Cap

$509.91 Million

CN¥3.48 Billion CNY

Market Cap Rank

#11867 Global

#3274 in China

Share Price

CN¥5.39

Change (1 day)

+5.27%

52-Week Range

CN¥4.88 - CN¥8.81

All Time High

CN¥19.74